NYSE:BCR', 'C. R. Bard Inc.', 'http://finnewsdaily.com/finnews.png');

CR Bard Incorporated (NYSE:BCR) Stock Is Shorted More

December 8, 2017 - By Winifred Garcia

 CR Bard Incorporated (NYSE:BCR) Stock Is Shorted More

Investors sentiment decreased to 0.58 in 2017 Q2. Its down 0.30, from 0.88 in 2017Q1. It fall, as 99 investors sold C. R. Bard, Inc. shares while 273 reduced holdings. 103 funds opened positions while 111 raised stakes. 55.14 million shares or 10.97% less from 61.93 million shares in 2017Q1 were reported.
Keybank Association Oh owns 2,880 shares or 0.01% of their US portfolio. Paloma Prtnrs Com invested in 6,570 shares or 0.02% of the stock. Papp L Roy holds 2.06% or 30,090 shares. Pioneer Commercial Bank N A Or reported 1.73% in C. R. Bard, Inc. (NYSE:BCR). Panagora Asset Management Inc owns 15,323 shares. Savant Cap Ltd reported 1,621 shares. 4,656 were accumulated by Amica Pension Fund Board Of Trustees. 130,633 were accumulated by Price T Rowe Assoc Md. Caisse De Depot Et Placement Du Quebec holds 0.15% or 189,581 shares. First Midwest Bancorporation Tru Division holds 0.15% or 3,817 shares. 2,700 were accumulated by Bluefin Trading Ltd Liability Corp. Vanguard Group reported 0.12% of its portfolio in C. R. Bard, Inc. (NYSE:BCR). Bryn Mawr Trust Com holds 0.46% of its portfolio in C. R. Bard, Inc. (NYSE:BCR) for 24,253 shares. Halcyon Prns Limited Partnership has 5.93% invested in C. R. Bard, Inc. (NYSE:BCR) for 81,447 shares. Levin Strategies L P reported 0.02% stake.

The stock of CR Bard Incorporated (NYSE:BCR) registered an increase of 8.9% in short interest. BCR’s total short interest was 1.22 million shares in December as published by FINRA. Its up 8.9% from 1.12 million shares, reported previously. With 414,400 shares average volume, it will take short sellers 3 days to cover their BCR’s short positions. The short interest to CR Bard Incorporated’s float is 1.7%.

The stock increased 0.06% or $0.19 during the last trading session, reaching $332.07. About 569,187 shares traded or 15.70% up from the average. C. R. Bard, Inc. (NYSE:BCR) has risen 40.70% since December 8, 2016 and is uptrending. It has outperformed by 24.00% the S&P500.

C. R. Bard, Inc., together with its subsidiaries, designs, makes, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. The company has market cap of $24.21 billion. The firm offers vascular products, such as percutaneous transluminal angioplasty catheters, chronic total occlusion catheters, guidewires, fabrics, meshes, introducers, and accessories; valvuloplasty balloons; peripheral vascular stents, self-expanding and balloon-expandable covered stents, and vascular grafts; vena cava filters; biopsy devices; and a range of minimally invasive devices for the treatment of peripheral vascular and end-stage renal diseases. It has a 43.8 P/E ratio. It also provides urology products, including Foley catheters to reduce the rate of urinary tract infections; fecal incontinence products; brachytherapy devices and radioactive seeds for the treatment of prostate cancer; intermittent urinary drainage catheters, and urine monitoring and collection systems; ureteral stents; specialty devices for stone removal procedures; surgical slings and pelvic floor repair products; catheter stabilization devices; and products for therapeutic hypothermia.

C. R. Bard, Inc. (NYSE:BCR) Ratings Coverage

Among 15 analysts covering CR Bard (NYSE:BCR), 4 have Buy rating, 0 Sell and 11 Hold. Therefore 27% are positive. CR Bard has $337 highest and $190 lowest target. $261.17’s average target is -21.35% below currents $332.07 stock price. CR Bard had 32 analyst reports since August 27, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Thursday, August 27 by Goldman Sachs. The company was maintained on Wednesday, October 11 by BMO Capital Markets. The firm has “Neutral” rating by Nomura given on Thursday, March 17. The firm has “Buy” rating given on Wednesday, April 12 by BMO Capital Markets. The stock of C. R. Bard, Inc. (NYSE:BCR) has “Overweight” rating given on Tuesday, January 3 by Morgan Stanley. The firm has “Hold” rating by Jefferies given on Wednesday, July 27. The firm has “Hold” rating by Cowen & Co given on Friday, July 28. The rating was maintained by Barclays Capital with “Equalweight” on Wednesday, July 27. The rating was maintained by Raymond James on Wednesday, April 26 with “”. The firm has “Hold” rating by Needham given on Friday, September 22.

Another recent and important C. R. Bard, Inc. (NYSE:BCR) news was published by Bizjournals.com which published an article titled: “What Jabil’s new director signals about the company’s future” on November 30, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.